References to "ongoing research" or "active clinical trials" appear constantly in regenerative medicine marketing — worth understanding concretely what that actually means for the current state of evidence.
The current trial landscape
Globally, roughly 224 clinical trials are investigating stem cell therapies specifically for osteoarthritis as of 2026 — a substantial, genuinely active area of research. Most of these trials remain in Phase I/II (safety and preliminary efficacy) rather than the large Phase III trials that typically support formal regulatory approval.
"Active clinical trials" is a genuinely accurate description of this field's research status — it also means most applications haven't yet reached the level of evidence that would support formal FDA/INVIMA approval for specific indications. Both things are true simultaneously.
What clinical trial phases actually mean
- Phase I: Primarily focused on safety in a small patient group
- Phase II: Expanded safety data plus preliminary efficacy signals
- Phase III: Large-scale trials, typically required for formal regulatory approval — the stage most orthopedic stem cell applications haven't yet reached
What this means for patients today
You're not waiting for research to begin — it's genuinely underway, in some areas robustly so. You are, however, making a treatment decision in a space where the highest tier of clinical evidence isn't yet established for most applications, which is exactly the honest framing this entire site is built around.
Where to find more specific, current trial information
Clinicaltrials.gov is a public, searchable database of registered trials, useful if you want to independently verify the current state of research for a specific condition you're considering treatment for.
Ready to talk to someone?
Message us on WhatsApp for a free, no-obligation consultation.